GHK-Cu vs Mazdutide
Side-by-side comparison of key properties, dosing, and research.
- Summary
- GHK-Cu is a naturally occurring copper complex that declines with age. It is one of the most studied anti-aging peptides, known for powerful skin rejuvenation, wound healing, and tissue remodeling effects.
- Mazdutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Innovent Biologics and Eli Lilly. Phase 2 trials in Chinese populations demonstrated up to 11.3% body weight reduction at 6 mg over 24 weeks. It also improves liver fat, glycemic control, and lipid profiles. Phase 3 trials are ongoing primarily in China.
- Half-Life
- 2–4 hours
- ~7 days
- Admin Route
- SubQ, Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 1–3 mg
- 1.5 mg → 3 mg → 4.5 mg → 6 mg
- Frequency
- 3–5 times per week
- Once weekly
- Key Benefits
- Reduces wrinkles and fine lines
- Improves skin firmness and elasticity
- Accelerates wound healing
- Reduces inflammation and oxidative damage
- Promotes hair growth and thickness
- Supports collagen and elastin production
- May improve overall skin health and appearance
- Resets aged fibroblast behavior
- Anti-fibrotic — reduces scar tissue formation
- Up to 11.3% body weight reduction at 24 weeks (Phase 2, 6 mg dose)
- Significant reduction in liver fat content (NAFLD/MASH potential)
- Improves HbA1c and fasting glucose in type 2 diabetes
- Favorable lipid profile changes (reduced triglycerides)
- Once-weekly subcutaneous dosing
- Potential for superior weight loss vs GLP-1 monotherapy
- Side Effects
- Temporary blue-green discoloration at injection site (from copper — harmless)
- Post-injection sting (brief)
- Skin irritation with topical use (rare)
- Nausea
- Vomiting
- Decreased appetite
- Diarrhea
- +3 more
- Stacks With
- —
- —